Printer Friendly

SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE U.K. LAUNCH OF 'LEUCOMAX'

 SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE U.K. LAUNCH OF 'LEUCOMAX'
 MADISON, N.J., Oct. 29 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) of Madison, N.J., and Sandoz Pharma Ltd. of Basel, Switzerland, announced today the launch in the United Kingdom of 'Leucomax' (molgramostim), a granulocyte macrophage colony stimulating factor (GM-CSF).
 The United Kingdom is the first European Community (EC) country to approve the product since it was recommended for approval in September by the EC's Committee for Proprietary Medicinal Products (CPMP). The product was jointly developed by Sandoz and Schering-Plough and will be co-marketed in the EC by the two companies.
 'Leucomax' represents an advance in cancer therapy, offering the potential to reduce morbidity and lessen the risk of infection in individuals whose immune systems are compromised. GM-CSF is one of a group of natural proteins that broadly stimulate the production of white blood cells, a key element of the body's defense against infection.
 The 'Leucomax' application was filed in August 1990 with the Medicines Control Agency of the United Kingdom, which served as the rapporteur country for the CPMP. The CPMP is the EC body for the review of applications for biotechnology and high-technology products.
 The Medicines Control Agency approved 'Leucomax' in hospitals for chemotherapy-induced neutropenia in cancer patients, to accelerate recovery after autologous bone marrow transplantation, and to combat ganciclovir (DHPG)-induced neutropenia in AIDS patients with cytomegalovirus retinitis, which in most cases leads to blindness.
 In addition to the United Kingdom, 'Leucomax' is marketed in Argentina, Ecuador, Finland, Israel, Mexico, Pakistan and Sweden, and approved for marketing in Chile, Norway and Russia. Schering-Plough and Sandoz have filed marketing applications for 'Leucomax' in most major countries.
 Sandoz and Schering-Plough are research-based companies engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.
 -0- 10/29/92
 /CONTACT: Steve Galpin Jr. of Schering-Plough, 201-822-7415, or Sandoz Press Office, 41-61-324-9001/
 (SGP) CO: Schering-Plough Corporation ST: New Jersey IN: MTC SU: PDT


SH -- NY011 -- 6414 10/29/92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1992
Words:331
Previous Article:SUNRISE MEDICAL REPORTS RECORD FIRST QUARTER EARNINGS
Next Article:MASCO CORPORATION ANNOUNCES RECORD QUARTERLY SALES, IMPROVED EARNINGS AND DIVIDEND INCREASE
Topics:


Related Articles
SCHERING-PLOUGH BRIEFS ANALYSTS ON RESEARCH PROGRESS, NEW PRODUCTS
SCHERING-PLOUGH SIGNS WORLDWIDE AGREEMENT TO DEVELOP AND MARKET CANCER DRUG
SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE THAT CPMP RECOMMENDS APPROVAL 'LEUCOMAX' IN EUROPEAN COMMUNITY
Pharmacopeia, Inc. Announces Research Milestone Achievement With Schering-Plough
Schering-Plough Announces Availability of FARESTON(R) as First-Line Treatment of Metastatic Breast Cancer
Schering-Plough Acquires ICN's European Rights to Oral Ribavirin for Treatment of Hepatitis C
Schering-Plough Licenses Cedax(R) Marketing Rights to DJ Pharma.
Schering-Plough to Acquire From Novartis International Marketing Rights to Leucomax(R).
Schering-Plough Announces Executive Appointments In Its European Region.
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters